October 17, 2017 4:01 PM ET

Pharmaceuticals

Company Overview of 3B Pharmaceuticals GmbH

Company Overview

3B Pharmaceuticals GmbH offers pharmaceutical research and development services. It offers peptide and ligand discovery and optimization; in-vivo imaging agent development; and radiotherapy tracer identification services. The company’s areas of focus include medicinal chemistry and analytics, nuclear medicine, and diagnostic products. It has a strategic partnership with Baxter Corp. 3B Pharmaceuticals GmbH was founded in 2008 and is based in Berlin, Germany.

Magnusstraße 11

Berlin,  12489

Germany

Founded in 2008

Phone:

49 30 6392 4317

Fax:

49 30 6392 4316

Key Executives for 3B Pharmaceuticals GmbH

3B Pharmaceuticals GmbH does not have any Key Executives recorded.

3B Pharmaceuticals GmbH Key Developments

3B Pharmaceuticals GmbH and Sovicell GmbH Introduce the Novel Service Offering for Plasma Protein Binding Analysis

3B Pharmaceuticals GmbH and Sovicell GmbH announced the launch of a novel service to reliably quantify the plasma protein binding capacity of drug candidates. The companies have developed EScalate, a mass-spectrometry assay based on Sovicell's proprietary equilibrium shift technology. 3B Pharmaceuticals will be the exclusive global service provider under a license from Sovicell which will supply 3B Pharmaceuticals with EScalate reagents.

Ipsen and 3B Pharmaceuticals Sign License Agreement for Novel Radiopharmaceuticals in Oncology

Ipsen and 3B Pharmaceuticals GmbH have signed an exclusive license agreement for novel radiopharmaceuticals in oncology. Ipsen acquires exclusive worldwide rights to develop and commercialize novel radiopharmaceuticals targeting the neurotensin receptor. Ipsen will focus on the development of the lead program currently in preclinical development for the treatment of pancreatic adenocarcinoma and potentially other oncology indications. Under the financial terms of the agreement 3B Pharmaceuticals will receive a licensing upfront payment and is eligible to receive development and regulatory milestones of up to €82 million for several indications as well as tiered royalties on world-wide annual net sales of products developed and commercialized by Ipsen.

Similar Private Companies By Industry

Company Name Region
3B Pharmaceuticals GmbH Europe
Accelsiors Group International Europe
Aenova Group GmbH Europe
Aenova Holding GmbH Europe
AiCuris GmbH & Co. KG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 3B Pharmaceuticals GmbH, please visit www.3b-pharmaceuticals.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.